This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(MedPage Today) -- CHICAGO -- For patients with ventricular tachycardia (VT) and ischemic cardiomyopathy, going right to catheter ablation improved outcomes compared with trying antiarrhythmic drugs first, the VANISH2 trial showed. Death or.
Background Hypertrophic cardiomyopathy (HCM) is commonly associated with atrial fibrillation (AF), but its impact on outcomes in real-world practice is uncertain. years) were enrolled in the EURObservational Research Programme (EORP) Cardiomyopathy/Myocarditis Registry. Methods Overall, 1739 adult patients with HCM (40.9%
Among patients with ventricular tachycardia and ischemic cardiomyopathy, catheter ablation as an initial therapy led to a lower risk of adverse outcomes than antiarrhythmic drug therapy.
male with pertinent past medical history including Atrial fibrillation, atrial flutter, cardiomyopathy, Pulmonary Embolism, and hypertension presented to the Emergency Department via ambulance for respiratory distress and tachycardia. Description : Regular Wide Complex Tachycardia at a rate of about 160. SVT with aberrancy?
A prehospital 12-lead was recorded: There is a regular wide complex tachycardia. The computer diagnosed this as Ventricular Tachycardia. There is a wide complex regular tachycardia at a rate of 226. Toothache, incidental Wide Complex Tachycardia Could it be fascicular VT or Bundle Branch VT ( i.e., idiopathic VT )?
The goal of the VANISH2 trial was to compare endocardial catheter ablation with conventional antiarrhythmic drug (AAD) therapy as a first-line treatment for infarct-related ventricular tachycardia (VT) in ischemic cardiomyopathy.
A patient in the ICU with significant underlying cardiac disease [HFrEF 30%, non-ischemic cardiomyopathy, LBBB s/p CRT-D (biventricular pacer), AVNRT s/p ablation a few yrs ago, hx sinus tachycardia while on max tolerated BB therapy] went into a regular wide-complex tachycardia after intubation for severe COPD exacerbation.
The best approach for ablating ventricular tachycardia (VT) targeting right ventricular free wall (RVFW) aneurysms in arrhythmogenic right ventricular cardiomyopathy (ARVC) remains undefined.
Implantable cardioverter defibrillator (ICD) prevents sudden cardiac death (SCD) in patients with ischemic cardiomyopathy (ICM). Catheter ablation has been shown to effectively reduce ventricular tachycardia (VT) recurrence, yet its efficacy in patients without an ICD implantation remains uncertain.
The ECG in Figure-1 — was obtained from a middle-aged woman with positional tachycardia and diaphoresis with change of position from suprine to sitting. My THOUGHTS on the ECG in Figure-1: The rhythm is sinus tachycardia at ~105/minute ( ie, The R-R interval is regular — and just under 3 large boxes in duration ).
Tachycardia-induced cardiomyopathy (TIC) is a unique cardiomyopathy, which is potentially reversible. Due to the presence of tachyarrhythmias in various cardiomyopathies, differentiating TIC from other non-reversible conditions can be challenging.
Tachycardia-induced cardiomyopathy refers to changes in cardiac structure and function that result from rapid arrhythmia and can manifest as a continuous or recurrent event. Cardiomyopathy induced by atrial ta.
Cardiac sarcoidosis (CS), a rare condition characterized by non-caseating granulomas, can manifest with symptoms such as atrioventricular block and ventricular tachycardia (VT), as well as mimic inherited cardiomyopathies. A 58-year-old woman presented with sustained VT with a prior diagnosis of hypertrophic cardiomyopathy (HCM).
Tachycardia-induced cardiomyopathy (TICM) is a reversible impairment of the left ventricular (LV) systolic function caused by persistent tachyarrhythmias. It is often difficult to identify macroscopic scar in patients with TICM by cardiac magnetic resonance imaging (MRI).
The ventricular tachycardia (VT) substrate in patients with non-ischemic cardiomyopathy (NICM) is complex in distribution and intramural location. Myocardial lipomatous metaplasia (LM) is vital to post-infarct VT circuitry, but not investigated in NICM VT circuitry yet.
Shortly after isoprenalin infusion was initiated, there were short runs of ventricular tachycardia. The granulomatous inflammation affects the heart, causing an infiltrative cardiomyopathy The most common manifestations of cardiac sarcoidosis are atrioventricular (AV) block and ventricular tachyarrhythmias (VT).
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a family inherited cardiomyopathy associated with ventricular arrhythmias. With the development of molecular biology, histology, imaging, and other dia.
Many genetic non-ischemic dilated cardiomyopathies (NICM) cause ventricular tachycardias (VT) originating from scar substrate identified as areas of low electrogram voltage. Substrate locations vary and the causes of scar are not well defined.
Catheter ablation is an effective tool to reduce ventricular tachycardia (VT) burden. There is a lack of robust data studying the intraprocedural characteristics and outcomes of VT ablation in patients with non-ischemic (NICM) versus ischemic cardiomyopathy (ICM).
Ventricular Tachycardia (VT) is an important cause of morbidity and mortality in structural heart Disease. Current literature is limited in direct comparison of VT in ischemic (ICM) compared to non-ischemic cardiomyopathy (NICM).
Catheter ablation (CA) is effective in the treatment of ventricular tachycardia (VT). Although some data suggest patients with non-ischemic cardiomyopathy (NCIM) have worse outcomes compared to those with an ischemic etiology (ICM), direct comparisons are scarcely reported.
A 50-something male with unspecified history of cardiomyopathy presented in diabetic ketoacidosis (without significant hyperkalemia) with a wide complex tachycardia and hypotension. Analysis: there is a wide complex tachycardia. This was the interpretation I put into the system: WIDE COMPLEX TACHYCARDIA. It is regular.
He had a background of arrhythmic right ventricular cardiomyopathy. He had previously undergone the placement of a dual-chamber implantable cardioverter-defibrillator for atrioventricular block and ventricular tachycardia (VT). Clinical introduction A man in his 50s presented to the emergency department with palpitations.
VF should make you think of ischemia, cardiomyopathy (especially scar from old MI), or one many other cardiac but non-ischemic etiologies. Confirmation of sinus tachycardia should be easy to verify when the heart rate slows a little bit ( as the patient's condition improves ) — allowing clearer definition between the T and P waves.
Abstract Introduction Due to its unique features, pulsed field ablation (PFA) could potentially overcome some limitations of current radiofrequency (RF) ventricular tachycardia (VT) ablation. Methods Two patients with ischemic cardiomyopathy and previously failed RF VT ablations were treated with PFA.
A 69-year-old man with a history of MI and cardiomyopathy presented with 2 days of dyspnea. Regular tachycardia (124 beats per min), diaphoresis, and rales were present. A diagnosis was made.
Objectives To describe a cohort of patients with arrhythmogenic left ventricular cardiomyopathy (ALVC), focusing on the spectrum of the clinical presentations. Twenty-one (41%) had normal echocardiogram, 13 (25%) a hypokinetic non-dilated cardiomyopathy (HNDC) and 17 (33%) a dilated cardiomyopathy (DCM).
Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is often accompanied by atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), which are difficult to control because beta-blockers and antiarrhythmic drugs can worsen heart failure (HF).
2. Baseline fibrotic substrate from dilated cardiomyopathy leading to VT. I interpreted the ECG as VT with two primary etiological possibilities: 1. Abrupt plaque ulceration of Type 1 ACS leading to VT. From a clinical standpoint I reconciled the first possibility as most probable since the chest discomfort came first.
In all-comers with significant VAs, the pooled rate of SHD post-CMR evaluation was 39% (24% in the subgroup of premature ventricular contractions and/or non-sustained ventricular tachycardia vs 63% in the subgroup of more complex VAs). A change in diagnosis after use of CMR ranged from 21% to 66% with a pooled average of 35% (29%–41%).
Surgical disarticulation of the right ventricular (RV) free wall has been described by Guiraudon and colleagues as an effective therapy for refractory ventricular tachycardia (VT) in arrhythmogenic right ventricular cardiomyopathy (ARVC).1
Belhassen’s ventricular tachycardia is an uncommon arrhythmia in infants. Originating near the left posterior fascicle, it is initiated by supraventricular ectopy or sinus tachycardia and is uniquely sensitive to verapamil. Use of verapamil in infants is controversial due to risk of severe hemodynamic compromise.
Supraventricular tachycardias are the most common arrhythmias that occur during pregnancy. Pharmacologic therapy is often preferred in pregnant patients. When pharmacologic therapy fails, fluoroless catheter ablation utilizing electroanatomic mapping systems and intracardiac echocardiography (ICE) may be considered.
IntroductionFocal atrial tachycardia (FAT) is predominant in the pediatric population. A 12-lead electrocardiogram revealed a narrow QRS complex tachycardia with a rate of 157 beats per minute and a prolonged RP relationship. Echocardiography indicated a severely reduced ejection fraction of 22%.
Cheng and Zhang to our paper1, we note that despite ARVC being a relatively uncommon cardiomyopathy, we uniquely report on a large clinical experience with very long-term follow-up after VT ablation and confirm a high incidence of atrial flutter (AFL) and the effectiveness and low risk of catheter ablation of AFL. In response to Drs.
Prior studies have shown efficacy of noninvasive radiation therapy using stereotactic body radiation therapy (SBRT) for treatment-refractory ventricular tachycardia (VT). Data is limited on comparison of ischemic (ICM) and nonischemic cardiomyopathy (NICM).
Atrial tachycardia (AT) originating from the left atrial appendage (LAA) is uncommon and the most difficult arrhythmia to eliminate. Therefore, we present the case of a 5-year-old girl with tachycardia-induced.
His previous echo one month prior shows the same thing: “consistent with old infarct in LAD vascular territory, with EF 45%” "I think there is something else causing his tachycardia which is exaggerating his EKG findings and mimicking an acute myocardial infarction." He had a h/o ischemic cardiomyopathy and right MCA stroke.
In hypertrophic cardiomyopathy (HCM), 48-hour ambulatory monitoring has been standard practice to detect nonsustained ventricular tachycardia (NSVT), a sudden death risk marker. Extended wear ambulatory ECG devices have more recently utilized for monitoring HCM patients.
Dilated cardiomyopathy with arrhythmic phenotype. Abstract Aims Dilated cardiomyopathy (DCM) with arrhythmic phenotype combines phenotypical aspects of DCM and predisposition to ventricular arrhythmias, typical of arrhythmogenic cardiomyopathy.
Main pathophysiological components influencing mortality in chronic Chagas cardiomyopathy. LV, left ventricular; PVC, premature ventricular contraction; VT, ventricular tachycardia. Chagas disease is a neglected tropical disease caused by the parasite Trypanosoma cruzi.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content